BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 12470127)

  • 1. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.
    Stein DJ; Versiani M; Hair T; Kumar R
    Arch Gen Psychiatry; 2002 Dec; 59(12):1111-8. PubMed ID: 12470127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.
    Wagner KD; Berard R; Stein MB; Wetherhold E; Carpenter DJ; Perera P; Gee M; Davy K; Machin A
    Arch Gen Psychiatry; 2004 Nov; 61(11):1153-62. PubMed ID: 15520363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
    Liebowitz MR; Gelenberg AJ; Munjack D
    Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
    Lepola U; Bergtholdt B; St Lambert J; Davy KL; Ruggiero L
    J Clin Psychiatry; 2004 Feb; 65(2):222-9. PubMed ID: 15003077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
    Seedat S; Stein MB
    J Clin Psychiatry; 2004 Feb; 65(2):244-8. PubMed ID: 15003080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
    Stein MB; Liebowitz MR; Lydiard RB; Pitts CD; Bushnell W; Gergel I
    JAMA; 1998 Aug; 280(8):708-13. PubMed ID: 9728642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic advances: paroxetine for the treatment of social anxiety disorder.
    Lydiard RB; Bobes J
    Depress Anxiety; 2000; 11(3):99-104. PubMed ID: 10875050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder.
    Rickels K; Mangano R; Khan A
    J Clin Psychopharmacol; 2004 Oct; 24(5):488-96. PubMed ID: 15349004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of the severity of social phobia.
    Montgomery SA
    J Affect Disord; 1998 Sep; 50 Suppl 1():S17-22. PubMed ID: 9851574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
    Stein MB; Fyer AJ; Davidson JR; Pollack MH; Wiita B
    Am J Psychiatry; 1999 May; 156(5):756-60. PubMed ID: 10327910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group.
    Baldwin D; Bobes J; Stein DJ; Scharwächter I; Faure M
    Br J Psychiatry; 1999 Aug; 175():120-6. PubMed ID: 10627793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials.
    Hedges DW; Brown BL; Shwalb DA; Godfrey K; Larcher AM
    J Psychopharmacol; 2007 Jan; 21(1):102-11. PubMed ID: 16714326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.
    Liebowitz MR; Stein MB; Tancer M; Carpenter D; Oakes R; Pitts CD
    J Clin Psychiatry; 2002 Jan; 63(1):66-74. PubMed ID: 11838629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa.
    Stein DJ; Berk M; Els C; Emsley RA; Gittelson L; Wilson D; Oakes R; Hunter B
    S Afr Med J; 1999 Apr; 89(4):402-6. PubMed ID: 10341825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study.
    Lader M; Stender K; Bürger V; Nil R
    Depress Anxiety; 2004; 19(4):241-8. PubMed ID: 15274173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine in social phobia.
    Mancini C; Ameringen MV
    J Clin Psychiatry; 1996 Nov; 57(11):519-22. PubMed ID: 8968300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
    Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
    J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.